DiffuseSandbox
AI-powered platform for rapid and scaled protein binder design
Platform · Cloud SaaSCompany source
Company profile
About Diffuse Bio
Diffuse Bio is a biotechnology company that develops generative AI systems for engineering novel and useful proteins with unprecedented control and accuracy. Founded by pioneers in generative AI for proteins, the company bridges the gap between AI research and biological reality through proprietary assay development and large-scale data generation. Diffuse Bio's platform enables the design of protein therapeutics in minutes on a laptop compared to weeks in a traditional lab setting. The company's core products include DiffuseSandbox for rapid AI binder design, RamaX Discovery for ultra-fast experimental binder screening, and RamaX Opt for affinity maturation and multi-objective sequence optimization. Their approach combines cutting-edge AI models with massive biological datasets, delivering one-shot precision designs that are performant on the first iteration without time-intensive lab-in-the-loop screens. The company has demonstrated the ability to achieve 10-1000x improvements in binding affinity within one week, while simultaneously optimizing for multiple objectives including sequence liability removal, humanization, and cross-species binding. Diffuse Bio serves pharmaceutical and biotechnology partners, accelerating protein discovery and development through validated AI-designed proteins. The company's research has been published in Nature and featured in major media outlets including The New York Times and NBC News.
Company description Diffuse Bio official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Diffuse Bio?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Antibody development
- Protein binders
- Protein therapeutics
Who it serves
- Biotechnology companies
- Pharma
Deployment & integration
Api Only · Cloud Saas · Other deployment with recorded integration context.
Geographic context
MarketsUSA
Company sourceOfficial website
Company milestones
Platform expansion
Published case study in June 2026 demonstrating >1000x tighter binders in 1 week. Launched RamaX platform for ultra-fast binder screening. Released DSG-2mini and DiffuseSandbox with public access. Published ProxyTm for protein thermostability measurement at scale.
Partnerships
Recorded partners
- Industry leaders in pharmaceutical and biotechnology sectors (specific names not disclosed)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
DSG-2mini
Latest generation protein generative AI model
Model · Api OnlyCompany source
ProxyTm
Novel method for measuring protein thermostability at scale
Platform · OtherCompany source
RamaX Discovery
Ultra-fast experimental platform for binder screening at scale
Platform · OtherCompany source
RamaX Opt
Fastest affinity maturation and multi-objective sequence optimization platform
Platform · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
10-1000x improved binding affinity
Achieved in one week using RamaX Opt platform across 4 therapeutic targets
One-shot precision designs
Performant on first design iteration without lab-in-the-loop screens
Ultra-fast affinity maturation
Fastest affinity maturation method available, completing optimization in one week
Multiple therapeutic targets case study
Simultaneous optimization of 4 parental VHHs against 4 different therapeutic targets (anti-CD3, anti-HER2, anti-IL7RA, anti-PD-L1) for affinity maturation and sequence liability removal
10-1000x improved binding affinity in 1 week while removing known sequence liabilities and screening targets in parallel
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Diffuse Bio
Recent articles published on Diffuse Bio's official website.
End-to-End Design with DiffuseSandbox and RamaXSupport for scaled-up binder design on DiffuseSandbox.
Read on Diffuse BioUltra-fast Binder Optimization with RamaX OptTo our knowledge, the fastest affinity maturation available.
Read on Diffuse BioProxyTm: Protein Thermostability at ScaleA new way to measure thermostability.
Read on Diffuse Bio>1000X Tighter Binders in 1 Week with RamaX OptA case study on sequence optimization.
Read on Diffuse BioBenchmarking Minibinder Library Screening in <2 Weeks with RamaXBenchmarking our minibinder discovery platform vs SPR.
Read on Diffuse Bio07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.